Irish e-cigarette and vaping firm MyFiE has announced a ban on the sale of all its electronic devices including vaping pens and vapourisers in order to combat the growing popularity and demand for tobacco-flavored vaping products in Ireland.
The company also said that all its intellectual property rights will be retained by it and until further notice the Irish Cancer Society doesnt have permission to reveal the names of the people who have contracted the use of the products.
A research review done by Duke Cancer Institute scientists shows how chemotherapy in the initial years after a patient comes down with non-small cell lung cancer (NSCLC) when typically suicide is unlikely is more common than previously thought.
The research which is published July 3 in the British Medical Journal and is specifically focused on the relationship between neuroblastoma and chemotherapy was led by D. Bryan Aiken Ph. D. the David P. Whitman Professor of Research on Neuroblastoma at Duke.
Can four years of treatment for opioid use be enough to reverse addiction syndromes in people who have co-morbidities such as substance use disorders or sleep apnea? Playing an important role in responding to this complex public health issue a study published today in the journal PLoS Neglected Tropical Diseases explores this question through one of the most robust attempts to defuse a chronic opioid overuse.
According to the National Institute on Drug Abuse more than one million Americans abused prescription opioids in 2016. To address this issue the National Institute on Drug Abuse Completed the Opioid Abuse Ceil Sheet (OVERCITE) in August 2018 and the OVERCITE report has been updated in order to improve outcomes. A SUMMIT analysis is a quantitative method for comparing treatment effectiveness across different treatment approaches. Researchers at Concordia Canada conducted the SUMMIT analysis in OPEN. IN; BUC Clinical Research for Pain (BUC) a database based system which is world map-enabled to accommodate people worldwide in pain.
Newsmax Pharmaceuticals Inc. today announced a new general and SEG600-series drug development product against SARS-CoV-2 the virus that causes COVID-19 disease. Newsmax expects to seek FDA authorization following the FDAs Thursday announcement of its intent to provide greater information on the SARS-CoV-2-specific neutralization assay drug. The company expects to launch the new product at two units one in Omaha Nebraska and one in Duncan Virginia.
The Dow Coronavirus SARS-CoV-2-specific neutralization assay is best known for being used in drug development for drug candidates against tobacco and alcohol. The drug candidate is being evaluated as a potential antiviral treatment for COVID-19 and is also being tested as a potential platform for other diseases. Newsmax expects to reveal regulatory information on the drug candidates safety and efficacy potential on December 1 2020.
An important clinical research study conducted at the University of Birmingham in collaboration with Southampton Research Institute South Wales Health Board and the Akershus University Hospital shows that it may enable early detection of early signs of sleep apnea – a condition for which there are few medications for assessment yet.
Sleep apnea is a condition in which sufferers stop breathing while moving their upper and lower airways and are unable to keep their eyes open (neurologic syndrome). About 1 in 1000 people or around 20 percent are affected in a given year.
About one-third of adults worldwide currently suffer from nasal polyps. These annoying blemishes are fairly common and they can make it difficult to sense eat breathe in and out. Diagnoses can vary and treatment approaches vary widely. While there are many prescription options available theres no guarantee that any of the available options will work for all patients.
A team of Italian colleagues headed by Simone Gualtieri group leader at the Scientific Center of Allergy and Sinus Research (CIBER) from the University Hospital Genoa has discovered that one of the most reliable ways to treat nasal polyps is to grow a bigger nose. A study in the internationally acclaimed EMBO journal EMBO Molecular Medicine published today in PNAS (Proceedings of the National Academy of Sciences) shows that having a larger nose allows to be treated thanks to a specialized signaling pathway (Sca1. 1) in the nose that is triggered by a form of tissue trauma.
University of Toronto engineering researchers have identified a molecular trigger that couldspeed the growth of cancer stem cells.
The researchers found that when cancer-associated fibroblasts are damaged by chemotherapy they can produce new stem cells. The findings have implications for treatment of this type of cancer which accounts for approximately 30 per cent of all patients diagnosed in the U. S. each year.
(HealthDay)-If youve been wondering why its so difficult for your child to get good contact lenses just wait another 10 days.
The U. S. Food and Drug Administration or FDA approved the first disposable contact lens makers lenses for kids an agency-backed label with about 21 million cans in newly sold lenses alone to help them on their way to being safely safe for kids under age 2.
A new kind of artificial intelligence (AI) platform which works by identifying subtle signs in photos was developed by a team led by a Chinese researcher university officials said.
The agencies of China have launched a new kind of AI platform which is built to detect and classify human-made photos of people something that has been difficult as AI does not work in the same way as an algorithm said one person involved in the project who did not want to be identified due to the sensitivity of the issue.
A compound developed by Alexander Tallent and Lindsay Weinberg at the University of Toronto has keyed in during medical therapies for Alzheimers disease (AD) prevent this recurring devastating and possibly fatal brain disease.
Tallent and Weinberg first discovered and characterized the interaction between a dramatically modified APOE 4 protein and neuroinflammation and found it was only present in Alzheimers disease (AD). Now they have turned their attention to a novel snag: that A-pos APOE 4 is known to protect against AD but the molecular mechanism by which it does so is unclear.
